News
NOTV
0.3100
+6.86%
0.0199
Weekly Report: what happened at NOTV last week (0420-0424)?
Weekly Report · 5d ago
Inotiv Receives Targeted Waiver on Liquidity Covenant Tests
TipRanks · 04/21 10:44
Inotiv lenders waive minimum liquidity covenant for April test dates
PUBT · 04/21 10:05
Weekly Report: what happened at NOTV last week (0413-0417)?
Weekly Report · 04/20 09:20
10 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 04/17 17:05
OpenAI launches GPT-Rosalind, an AI model for life sciences research
Seeking Alpha · 04/17 10:27
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 04/16 17:06
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 04/16 12:07
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 04/15 17:05
Weekly Report: what happened at NOTV last week (0406-0410)?
Weekly Report · 04/13 09:21
Inotiv Secures Targeted Waiver for Short-Term Liquidity Covenants
TipRanks · 04/07 10:45
Inotiv lenders waive minimum liquidity covenant for April test dates under credit agreement
Reuters · 04/07 10:02
Weekly Report: what happened at NOTV last week (0330-0403)?
Weekly Report · 04/06 09:21
Weekly Report: what happened at NOTV last week (0323-0327)?
Weekly Report · 03/30 09:21
Inotiv Secures Short-Term Liquidity Covenant Waiver From Lenders
TipRanks · 03/24 10:32
Inotiv lenders grant waiver of minimum liquidity covenant under credit agreement
Reuters · 03/24 10:03
Weekly Report: what happened at NOTV last week (0316-0320)?
Weekly Report · 03/23 09:21
FDA issues guidance on alternatives to animal testing
Seeking Alpha · 03/18 16:38
Weekly Report: what happened at NOTV last week (0309-0313)?
Weekly Report · 03/16 09:20
Inotiv Secures Temporary Waiver on Credit Agreement Liquidity Covenant
TipRanks · 03/10 12:25
More
Webull provides a variety of real-time NOTV stock news. You can receive the latest news about Inotiv Inc through multiple platforms. This information may help you make smarter investment decisions.
About NOTV
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.